SEC Form 4	
FORM 4	

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CH
Instruction 1(b).	Filed pursuant to Se

TATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934	
or Section 30(h) of the Investment Company Act of 1940	

1. Name and Address of Reporting Person [*] ALTSCHULLER Susan					2. Issuer Name and Ticker or Trading Symbol <u>Mural Oncology plc</u> [MURA]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last)	(Fii)	3. Date of Earliest Transaction (Month/Day/Year) 08/14/2024										er (give title w)		Other (below)	specify			
C/O MURAL ONCOLOGY PLC 10 EARLSFORT TERRACE (Street) DUBLIN 2 L2 D02 T380					4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable te) Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	· 		Zip)		Rule 10b5-1(c) Transaction Indication Image: Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Table	e I - N	on-Deriva	tive S	Secui	rities	s Ac	quire	d, Di	sposed o	f, or E	Benefic	ally Ow	ned				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day)			Year) if any		ution Date,				4. Securities Disposed Of			5) Secu Bene Owne			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)				
									Code	v	Amount	(A) or (D)	Price	Trans	Transaction(s) (Instr. 3 and 4)				
Ordinary	Ordinary Shares			08/14/2024				Р		10,000	Α	\$3.207	1(1)	0,000	D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. 3. Transaction Date (Month/Day/Year) Price of Derivative Security 34. Deemed Execution Date, (Month/Day/Year) (Month/Day/Year)		ution Date,	4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4) Amoun		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y Dire or Ir (I) (I	nership n: ct (D) ndirect nstr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$3.17 to \$3.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Date Exercisable Expiration

Date

/s/ Maiken Keson-Brookes, attorney-in-fact for Susan Altschuller

or Number

Shares

Title

08/15/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

v

(A) (D)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.